In addition to feeding into the opioid crisis, the COVID-19 pandemic exposed deficiencies in the comprehensive treatment of pain. During the pandemic, regulators reined in local, regional and federal rigamarole that previously governed innovation in the field of telehealth. Waived temporarily were the local, regional and national health policies that made the reality of virtual care ponderous.
At the time, leading experts openly questioned whether the explosion in virtual visits for pain